This document summarizes COVID-19 vaccine safety published studies and survey results in map form. Full results can be found on the VIEW-hub COVID safety module.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.

This document outlines the methods used in the COVID-19 vaccine safety literature review presented in the VIEW-hub COVID safety studies module.

In partnership with the Asian Development Bank, IVAC summarized the evidence for COVID-19 vaccine performance against Omicron sub-variants.

These forest plots summarize the available evidence on the vaccine effectiveness of the bivalent Omicron-containing mRNA COVID-19 vaccines.

This document provides an overview of the available laboratory evidence on the ability of the bivalent Omicron-containing mRNA COVID-19 vaccines to neutralize Omicron subvariants.

In partnership with the Asian Development Bank, IVAC developed factsheets summarizing key measures for COVID-19 vaccines such as effectiveness and protection against severe disease.

In partnership with the Asian Development Bank, IVAC developed factsheets summarizing key measures for COVID-19 vaccines such as effectiveness and protection against severe disease.

In partnership with the Asian Development Bank, IVAC summarized the landscape, benefits, and challenges of next generation COVID-19 vaccines.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.